STAT3 and cancer: Our findings are clinically relevant since CNL is currently being investigated in a first-in-human phase I 3+3 dose escalation clinical trial in solid tumors (NCT02834611) at the University of Maryland, University of Virginia and Medical University of South Carolina.34 This work thus opens up a wide avenue of research directed toward examining the ceramide-STAT3 drug-target combination in other cancer models.